Christopher Hui: The Hong Kong Stock Exchange has taken into account the needs of different investors when implementing the optimized mechanism for IPO pricing and allocation.

Xu Zhengyu mentioned that the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange will continue to closely review the quality of sponsor work and listing applications, and take appropriate regulatory actions when necessary to uphold Hong Kong's reputation as a leading international fundraising hub.

Zhitong FinanceMay 13 13:51

Lynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA

PR NewswireApr 10 20:00

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis

PR NewswireMar 2 20:00

At a Glance: March's Hottest IPOs - Shangmi Technology Approved! Four New Stocks, Including ZhaoWei Electromechanical and EastControl, Undergoing Enthusiastic Subscription.

Hello, fellow investors! The New Stock Observer is here to provide updates on the popular HK IPOs in March and throughout 2026. Fellow investors, check it out now!

Futu NewsFeb 28 09:55

IPO News | Linkhealth Pharmaceuticals Plans to List on the Hong Kong Stock Exchange; China Securities Regulatory Commission Requests Supplementary Explanation on the Legality and Compliance of the Company’s Establishment and Past Equity Changes

The China Securities Regulatory Commission (CSRC) released the 'Supplementary Material Requirements for Overseas Issuance and Listing Filings (January 12, 2026 – January 16, 2026).'

Zhitong FinanceJan 19 13:58

Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib (LNK01001) in Rheumatoid Arthritis

PR NewswireJan 12 20:00